Baird Financial Group
VIR icon

Baird Financial Group’s Vir Biotechnology VIR Stock Holding History

Baird Financial Group’s Portfolio VIR Stock Details VIR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-10,204
Closed -$103K – 1806
2023
Q4 		$103K Buy
+10,204
New +$93.2K ﹤0.01% 1677

Other funds holding VIR

SIAU
SB Investment Advisers (UK) London, United Kingdom $7.73B AUM 2.35% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
GF
Gates Foundation Seattle, Washington $43.5M AUM 14.19% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Baird Financial Group's VIR Position: Q1 2024 in Review

Baird Financial Group sold out of Vir Biotechnology (VIR) in Q1 2024, closing a stake of 10,204 shares — an estimated $103K sold.

Baird Financial Group first reported a position in VIR in Q4 2023 and held it in 1 quarter. The position peaked at $103K in Q4 2023. 209 funds tracked by Wall St. Rank hold VIR as of Q1 2024.

  • Baird Financial Group reported no remaining Vir Biotechnology position as of Q1 2024 after selling out during the quarter.
  • Baird Financial Group sold 10,204 Vir Biotechnology shares in Q1 2024, an estimated $103K.
  • Baird Financial Group first reported a position in Vir Biotechnology in Q4 2023 and held it in 1 quarter.
  • Baird Financial Group's Vir Biotechnology position peaked at $103K in Q4 2023.
  • 209 funds tracked by Wall St. Rank held Vir Biotechnology as of Q1 2024.

Based on Baird Financial Group's 13F filing for Q1 2024, filed 14 May 2024.